Sinopharm unit gets approval for clinical trials of mRNA COVID vaccine
BEIJING, Jan 20 (Reuters) - Sinopharm's 1099.HK
biotech unit has obtained regulatory approval for clinical
trials of its mRNA COVID-19 vaccine against the Omicron variant,
the company said on Friday.
The unit, based in the commercial hub of Shanghai, has built
a research and development platform, as well as workshops with
annual production capacity of 2 billion doses of mRNA vaccine,
Sinopharm added.
(Reporting by Beijing newsroom; Editing by Clarence Fernandez)
((Ella.Cao@thomsonreuters.com;))
Recent news on Sinopharm
See all newsBrief: Sinopharm Group Says 9M Sinopharm Accord Net Income Attributable RMB952.5 Million (Oct 20)
Medical products distributor Sinopharm Group's prelim 9-month revenue slips
Brief: BlackRock's Long Position In H Shares Of Sinopharm Reduces To 9.23% On Oct 13, HKEX Shows
Sinopharm interim revenue edges down on softness in pharmaceutical distribution business
Brief: Sinopharm Group To Sell 30.13% Stake In China National Medicines Guorui Pharmaceutical For